Phase III Randomized Study Of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy And Consolidation Therapy In Actively Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia Read more
An Open-Label, Randomized Phase 3 Study Of MK-6482 Versus Everolimus In Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 And VEGF-Targeted Therapies Read more
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Of Infigratinib For The Adjuvant Treatment Of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302) Read more
A Study Of Enfortumab Vedotin (ASG-22CE) As Monotherapy Or In Combination With Other Anticancer Therapies For The Treatment Of Urothelial Cancer Read more
Phase III Randomized Trial Of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery Or Radiation) Of The Primary Tumor In Metastatic Prostate Cancer Read more
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With Or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer Read more
Intuitive Surgical, Protocol: ISI-IRIS-002 , PI: Dr. Stifelman, Title: A Prospective Post-Market Study To Evaluate The Clinical Utility Of IRISTM, A Three-Dimensional (3-D) Anatomical Modeling Software For Pre-Operative Surgical Planning And Intra-Operative Navigation For Nephrectomy Read more
A Phase I/II Study Evaluating The Dosing, Safety, Efficacy, And Biological Activity Of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Neoadjuvant Chemotherapy (NACT) In Patients Actively Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer Read more
A Phase Ib Safety Run-In And Randomized Phase II, Open-Label Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of M6620 In Combination With Avelumab And Carboplatin In Comparison To Standard Of Care Therapy In Participants With Parpi-Resistant Recurrent Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Read more
